Global Rosuvastatin and Ezetimibe Tablets Market Strategic Research Report

Scope of the Report

The global Rosuvastatin and Ezetimibe Tablets market size is predicted to grow from US$ 127 million in 2025 to US$ 839 million in 2032; it is expected to grow at a CAGR of 15.6% from 2026 to 2032.

Rosuvastatin and Ezetimibe Tablets are a fixed-dose combination lipid-lowering drug formulated with rosuvastatin and ezetimibe. Through dual synergistic mechanisms—inhibiting hepatic cholesterol synthesis and blocking intestinal cholesterol absorption—they potently reduce total cholesterol, low-density lipoprotein cholesterol and triglycerides, while moderately increasing high-density lipoprotein cholesterol.

This product is mainly indicated for primary hypercholesterolemia and mixed hyperlipidemia, and can also be used as adjunctive therapy for homozygous familial hypercholesterolemia. It is suitable for patients who fail to achieve adequate lipid control with statin monotherapy. Featuring high lipid-lowering efficacy, good medication adherence and controllable safety, it is a commonly used compound preparation in clinical lipid management and cardiovascular risk prevention.In 2025, global Rosuvastatin and Ezetimibe Tablets production reached approximately 250 million bottles.

Rosuvastatin Ezetimibe Tablets are a combination formulation of rosuvastatin and ezetimibe, primarily used to treat hypercholesterolemia and reduce the risk of cardiovascular events. With the rising global incidence of cardiovascular diseases and increasing public health awareness, the demand for cholesterol-lowering drugs continues to grow. Rosuvastatin Ezetimibe Tablets, with their dual lipid-lowering action, effectively reduce low-density lipoprotein cholesterol (LDL-C), making them especially suitable for patients who do not respond well to single statin therapy or other lipid-lowering treatments. As a result, they have broad application prospects in high-risk cardiovascular disease patients.

In terms of market demand, due to the high prevalence of cardiovascular diseases, the demand for Rosuvastatin Ezetimibe Tablets shows a sustained growth trend. This is especially true in an aging society and against the backdrop of increasing lifestyle-related diseases, where more patients require more comprehensive treatment approaches to control cholesterol levels.

Key Questions Addressed in this Report

What is the 10-year outlook for the global Rosuvastatin and Ezetimibe Tablets market?

What factors are driving Rosuvastatin and Ezetimibe Tablets market growth, globally and by region?

Which technologies are poised for the fastest growth by market and region?

How do Rosuvastatin and Ezetimibe Tablets market opportunities vary by end market size?

How does Rosuvastatin and Ezetimibe Tablets break out by Type, by Application?

This report presents a comprehensive overview of the global Rosuvastatin and Ezetimibe Tablets market, covering market size and forecast, segmentation by product type and application, competitive landscape, leading players and regional and country-level outlook.

Segment by Type

• Hospital
• Retail
• Online

Segment by Dosage Form

• ：Film-coated Tablets
• Sustained-release Tablets

Segment by Specification

• 10 mg/10 mg
• 10 mg/5 mg

Segment by Production Technology

• Original Drug
• Generic Drug

Segment by Application

• Hypercholesterolemia
• Cardiovascular
• Coronary Artery Disease
• Myocardial Infarction
• Others

Who Can Use This Report?

This report is written for decision-makers who need a clear, data-backed view of the global Rosuvastatin and Ezetimibe Tablets market:

• Manufacturers, suppliers and solution providers benchmarking their position and planning product, capacity and go-to-market strategy
• Distributors, channel partners and end users in Hypercholesterolemia, Cardiovascular, Coronary Artery Disease evaluating demand and sourcing options
• Investors, financial analysts and consultants assessing growth opportunities, competitive dynamics and M&A potential
• Government agencies, industry associations and research institutions tracking industry developments and policy impact